New Patented Medicines Reported to PMPRB

Up to date as of November 9, 2022

Search by:

to

* Note: Drugs with Price Review Records linked from the brand name are only available from 2010 onward (records for 2011 will be populated over the next few months). Summary Reports are available for drug products reported prior to 2010.


YearCompanyBrand NameChemical NameDINTherapeutic UseDate of First SaleStatus
2021Abbvie CorporationRinvoq - 30 mg/tabletupadacitinib02520893treatment of refractory moderate to severe atopic dermatitis01 Nov 2021Within Guidelines
2021Amgen CanadaKanjinti - 150 mg/vialtrastuzumab02518244Cancer07 Oct 2021Within Guidelines
2021Amgen Canada Inc.Amgevita - 20 mg/syringeadalimumab02459310Rheumatoid arthritis19 Feb 2021Within Guidelines
2021Amgen Canada Inc.Amgevita - 40mg/auto-injectoradalimumab02459302Rheumatoid arthritis19 Feb 2021Within Guidelines
2021Amgen Canada Inc.Amgevita - 40mg/syringe adalimumab02459299Rheumatoid arthritis19 Feb 2021Within Guidelines
2021Amgen Canada Inc.Riabni - 10 mg/mLrituximab02513447Cancer21 Apr 2021Within Guidelines
2021Astrazeneca Canada Inc.Enhertu - 100 mg/vialtrastuzumab deruxtecan02514400Cancer08 Jul 2021Subject to Investigation
2021Astrazeneca Canada Inc.Fasenra Pen - 30 mg/dosebenralizumab02496135Eosinophilic asthma13 Jan 2021Within Guidelines
2021Avir Pharma Inc.Jorveza - 0.5 mg/tabletbudesonide02513854Eosinophilic esophagitis19 Oct 2021Under Review
2021Avir Pharma Inc.Jorveza - 1 mg/tabletbudesonide02493675Eosinophilic esophagitis07 Jan 2021Subject to Investigation
2021Bayer Inc.Verquvo - 10 mg/tabletvericiguatChronic Heart Failure19 May 2021Under Review
2021Bayer Inc.Verquvo - 2.5 mg/tabletvericiguatChronic Heart Failure19 May 2021Under Review
2021Bayer Inc.Verquvo - 5 mg/tabletvericiguatChronic Heart Failure19 May 2021Under Review
2021Bayer Inc.Xarelto - 1 mg/mLrivaroxaban02510162Prevention of venous thromboembolic events11 Jun 2021Within Guidelines
2021Bayer Inc.Xarelto - 1 mg/mLrivaroxaban02510170Prevention of venous thromboembolic events11 Jun 2021Within Guidelines
2021BeiGene Ltd.Brukinsa - 80 mg/capsulezanubrutinib02512963Cancer01 Mar 2021Within Guidelines
2021BGP Pharma ULCCreon Minimicrospheres - 35000 unit/capsulepancreatin02494639Pancreatic exocrine insufficiency10 Feb 2021Does Not Trigger Investigation
2021Biomarin Pharmaceuticals Canada Inc.Vimizim - 1 mg/mLelosulfase alfa02427184Mucopolysaccharidosis type IVA27 Aug 2014Does Not Trigger Investigation
2021Celegene CorporationOnureg - 200 mg/tabletazacitidine02510197Acute myeloid Leukemia25 Nov 2021Within Guidelines
2021Celegene CorporationOnureg - 300 mg/tabletazacitidine02510200Acute myeloid Leukemia25 Nov 2021Within Guidelines
2021CSL Behring Canada Inc.Hizentra - 200 mg/mLimmune globulin subcutaneous (human)02498251Immune Deficiency13 May 2021Within Guidelines
2021Dutch Ophthalmic Research Center (International) B.V.Tissueblue - 0.25 mg/mLbrilliant blue g ophthalmic solution02510995Ophthalmic surgical dye30 Sep 2021Subject to Investigation
2021Eli Lilly CanadaEmgality - 100 mg/mLgalcanezumab02505134Migraine11 Jan 2021Under Review
2021Emd Sereno CanadaTepmetko - 225 mg/tablettepotinib02516322Cancer07 Oct 2021Within Guidelines
2021Gilead Sciences Canada Inc.Trodelvy - 180 mg/vialsacituzumab govitecan02520788Cancer22 Nov 2021Under Review
2021Glaxosmithkline Inc.Trelegy Elipta - 287.5 mcg/dosefluticasone furoate/umeclidinium/vilanterol02515776Chronic obstructive pulmonary disease (COPD)13 Sep 2021Within Guidelines
2021Hoffmann-La Roche LimitedEvrysdi - 0.75 mg/mLrisdiplam02514931Spinal Muscular Atrophy20 May 2021Within Guidelines
2021Hoffmann-La Roche LimitedPhesgo 80/40 - 120 mg/mLpertuzumab/trastuzumab02512912Cancer14 Apr 2021Subject to Investigation
2021Hoffmann-La Roche LimitedPhesgo 60/60 - 120 mg/mLpertuzumab/trastuzumab02512920Cancer14 Apr 2021Subject to Investigation
2021Hoffmann-La Roche LimitedPolivy - 30 mg/vialpolatuzumab vedotin02515431Lymphoma26 Oct 2021Under Review
2021Incyte Biosciences Canada CorporationMinjuvi - 200 mg/vialtafasitamab02518627Cancer29 July 2021Under Review
2021Indivior Canada Ltd.Suboxone 4/1 - 5 mg/filmbuprenorphine/naloxone 02502321Opioid Dependance17 Jun 2021Under Review
2021Insmed Incorporated Arikayce - 590 mg/vialamikacin liposome inhalation suspension (ALIS)Antibiotic 13 Jul 2021Subject to Investigation
2021Janssen Inc.Ponvory ponesimod02515474Multiple sclerosis1 Nov 2021Within Guidelines
2021Janssen Inc.Ponvory - 20 mg/tabletponesimod02515482Multiple sclerosis1 Nov 2021Within Guidelines
2021Janssen Inc.Janssen COVID-19 Vaccine - 0.5 mL/doseSARS-CoV-2 Vaccine [Ad26.COV2.S, recombinant]02513153COVID-1912 Apr 2021Under Review
2021Janssen Inc.Opsynvi - 50 mg/tabletmacitentan/tadalafil02521083Pulmonary arterial hypertension25 Nov 2021Within Guidelines
2021Kyowa Kirin Inc.Poteligeo - 4 mg/mLmogamulizumab 02527715 Cancer09 March 2021Under Review
2021Medison CanadaQinlock - 50 mg/tabletripretinib02500833Cancer10 Dec 2020Within Guidelines
2021Medison CanadaTavalisse - 100 mg/tabletfostamatinib02508052Chronic Immune Thromocytopenia10 Dec 2020Within Guidelines
2021Medison CanadaTavalisse - 150 mg/tabletfostamatinib02508060Chronic Immune Thromocytopenia10 Dec 2020Within Guidelines
2021Novartis Pharmaceuticals Canada Inc.Kesimpta - 20 mg/penofatumumab02511355Multiple sclerosis08 Apr 2021Within Guidelines
2021Organon Canada IncHadlima - 40 mg/syringeadalimumab02473097Rheumatoid arthritis19 Feb 2021Within Guidelines
2021Organon Canada IncHadlima Push Touch - 40 mg/auto injectoradalimumab02473100Rheumatoid arthritis19 Feb 2021Within Guidelines
2021Paladin Labs Inc.Xydalba - 500 mg/vialdalbavancin02480522Antibiotic 28 May 2021VCU
2021Pfizer Canada Braftovi - 75 mg/capsuleencorafenib02513099Cancer02 Nov 2021Within Guidelines
2021Pfizer Canada ULCMektovi - 15 mg/tabletbinimetinib02513080Antineoplastic agent, protein kinase inhibitor02 Nov 2021Within Guidelines
2021Sanofi-Aventis CanadaDupixent - 300 mg/auto-injectordupilumab02510049Atopic dermatitis27 May 2021Subject to Investigation
2021Searchlight Pharma Inc.Nextstellis 15/3 - 18 mg/tabletestetrol monohydrate/drospirenone02513218Oral Contraceptive15 Jun 2021Under Review
2021SpringWorks Therapeutics, Inc. Nirogacestat - 10 mg/tabletnirogacestatCancer27 Apr 2021Under Review
2021SpringWorks Therapeutics, Inc. Nirogacestat - 100 mg/tabletnirogacestatCancer27 Apr 2021Under Review
2021SpringWorks Therapeutics, Inc. Nirogacestat - 50 mg/tabletnirogacestatCancer27 Apr 2021Under Review
2021Sunovion Pharmaceuticals Canada Inc.Cequa - 0.9 mg/mLcyclosporine ophthalmic solution02512629keratoconjunctivitis sicca04 Nov 2021Within Guidelines
2021Takeda Canada Inc.Adynovate - 1000 IU/vialantihemophilic Factor (Recombinant), PEGylated02498588Hemophilia A18 Aug 2021Within Guidelines
2021Takeda Canada Inc.Adynovate - 250 IU/vialantihemophilic Factor (Recombinant), PEGylated02498537Hemophilia A19 Jul 2021Within Guidelines
2021Takeda Canada Inc.Adynovate - 500 IU/vialantihemophilic Factor (Recombinant), PEGylated02498545Hemophilia A18 Aug 2021Within Guidelines
2021Takeda Canada Inc.Takhzyro - 150 mg/mLlanadelumab02505614Cancer19 Jan 2021Within Guidelines
2021Teva Canada Innovation G.P.-S.E.N.C.Ajovy - 225 mg/auto-injectorfremanezumab02509474Migraine01 Apr 2021VCU
2021Ultragenyx Pharmaceuticals Inc.Dojolvi - 1000 mg/mLtriheptanoin02512556Lipid metabolism01 Apr 2021Within Guidelines
2021Vertex Pharmaceuticals Canada Inc.Kalydeco - 25 mg/packivacaftor02519364Cancer01 Sep 2021Within Guidelines